All News

Telemedicine

AI meets Rheumatology: ChatGPT and patient response optimization

d Bella Mehta, MBBS, MS

Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.

Read Article
OP0018 @RheumNow #EULAR2024 🔎 Study looked at early RA patient trajectories through time-independent disease state 📊 Authors demonstrated 4⃣ trajectories in early RA 🦴 Inflammation in joints, blood & poor response are main discriminatory factors https://t.co/IeDIU3jg9B

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
➡️ OP0064 @RheumNow #EULAR2024 ➡️ Non-articular pain (NAP) at early RA diagnosis & evolution over the first yr of RA treatment ➡️ NAP, esp regional NAP, common in early RA during 1st yr ➡️ NAP in axial, both upper quadrants and both lower quadrants common https://t.co/FOGcS05Z25

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
OP0086 #EULAR2024 @RheumNow #EULARBest Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action 1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.

Mrinalini Dey DrMiniDey ( View Tweet)

TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversion No difference between ttmts (and also no seroconversion) No diff in disease activity No diff in ACPA change wt wk52 @RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
200 millions pts PSO 1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi 2nd line ttmt, IL12-23i 32% & IL-23i 31% IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs Can't exclude some channeling bias, but that's a big signal! @RheumNow OP0010 #EULAR2024 #EULARBest

Aurelie Najm AurelieRheumo ( View Tweet)

AMPLIFIED RCT, 300+ pts ABA NOT (!) superior to ADA in dual seropositive SE+ MTX IR RA pts ACR50 rate high in both gps ABA 59% vs ADA 64% No new safety signal Defeating the encouraging data from smaller trials Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.

Dr. John Cush RheumNow ( View Tweet)

What is the origin of pain in difficult to manage axSpA? 1- Inflammation 2- Degenerative 3- Central Nervous System #EULAR2024 NZ https://t.co/KzATnYN4HG

Links:

Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Ph III RCT SHR0302 JAK1 selective inhibitor in RA 500+ pts ACR20 wk 24 SHR0302 8mg & 4mg PBO 75% 70% 40% ACR70 wk 24 SHR0302 8mg & 4mg PBO 31% 22% 7% Safety similar other JAKi Abstr#OP0037 #EULAR24 @RheumNow https://t.co/6ZuvT6czo8

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.

Bella Mehta bella_mehta ( View Tweet)

Great 1st #EULAR2024 scientific session: “Asymptomatic” Hyperuricemia — innocent bystander vs. menacing foe. Data re: effects on joints, kidneys, & heart have not supported clear clinical consequences w/ exception of kidney crystal deposition. TIGER Study results eagerly awaited. https://t.co/IPQU3Ww0NA

Links:

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Final prep in my hotel room for tomorrow’s big #EULAR2024 opening debate: this David up against the metaphorical (if not physical) Goliath, @Janetbirdope. Data does not adequately justify this JAKi regulatory safety warning, tomorrow I’ll tell you why. Details below ⬇️ @RheumNow https://t.co/rwFtYRlpLY

Links:

David Liew drdavidliew ( View Tweet)
#EULAR204 Encouraging Timeline for future potential treatments for #SLE #Lupus @LUPUSUK @LupusMadrid @Lupus_Chat @LupusEurope https://t.co/SLKc0XCtFq

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6

Links:

TheDaoIndex KDAO2011 ( View Tweet)
What is new in RA at #EULAR2024? Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future! https://t.co/ttYdElWlBY @RheumNow

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

🚨New(ish) MoA in RA Abiprubart anti-CD40 mAb Blocks T cell activation Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO Small sample n=25 per gpe Safety profile acceptable To be continued... Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Substudy of SELECT-COMPARE trial Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX ✔️ HUmorale response 71% ✔️ Cellular response 65% ✔️ No serious AEs ✔️ One event of HZ occurred during follow up Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24 T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology

TheDaoIndex KDAO2011 ( View Tweet)

×